2022. ENTERPRISE

Phase 4/VDZ/ perianal CD/Response

Mod-severe CD and 1-3 perianal fistulae on MRI were randomised to 2 vedolizumab regimens:

- VDZ doses 0,2,6,14 and 22 weeks.
- VDZ doses 0,2,6,10,14 and 22 weeks.

<u>Primary endpoint:</u> \geq 50% decrease from baseline in the number of draining perianal fistulae at week 30, where closed fistulae are no longer draining despite gentle finger compression


Results:

- Overall 53.6% ≥50% decrease from baseline of draining fistulae.
- VDZ standard 64.3% vs VDZ+w10dose 42.9%

Conclusion:

Sustained improvements in fistulizing CD were seen with both vedolizumab regimens. An additional dose at week 10 does not appear to alter treatment outcomes. Safety profile was consistent with other vedolizumab studies.

Efficacy and Safety of 2 Vedolizumab Intravenous Regimensfor Perianal Fistulizing Crohn's Disease: ENTERPRISE Study



of draining perianal fistulae at week 30

Z